Skip to main content
EJNMMI Research

Table 1 Clinicopathologic and operative characteristics of all breast cancer patients and subdivided by breast cancer subtype

From: Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype

 

ER+/HER2- (n = 33)

HER2+ (n = 16)

TN (n = 20)

Total (n = 69)

Age (years, range)

    

 Median

55 (38–80)

50 (36–68)

52 (37–73)

52 (36–73)

Tumor size (mm, range)

    

 Median

33 (13–90)

39 (8–87

45 (11–77)

41 (8–90)

cT status (n, %)

    

 cT1

2 (6.3%)

1 (6.3%)

1 (5.0%)

4 (5.9%)

 cT2

20 (62.5%)

10 (62.5%)

10 (50.0%)

40 (58.8%)

 cT3

8 (25.0%)

5 (31.3%)

9 (45.0%)

22 (32.4%)

 cT4

2 (6.3%)

0 (0.0%)

0 (0.0%)

2 (2.9%)

cN status (n, %)

    

 cN0

7 (21.2%)

4 (25.0%)

4 (20.0%)

15 (21.7%)

 cN1

22 (66.7%)

6 (37.5%)

11 (55.0%)

39 (56.5%)

 cN2-3

4 (12.1%)

6 (37.5%)

5 (25.0%)

15 (21.7%)

PET-positive nodes (n, %)

    

 0

10 (30.3%)

5 (31.3%)

4 (20.0%)

19 (27.5%)

 1–3

15 (45.5%)

9 (56.3%)

11 (55.0%)

35 (50.7%)

 ≥ 4

8 (24.2%)

2 (12.5%)

5 (25.0%)

15 (21.7%)

Histology (n, %)

    

 Invasive NST

31 (93.9%)

14 (87.5%)

18 (90.0%)

63 (91.3%)

 ILC

2 (6.1%)

1 (6.3%)

0 (0.0%)

3 (4.3%)

 Other

0 (0.0%)

1 (6.3%)

2 (10.0%)

3 (4.3%)

ER (n, %)

    

 Negative

0 (0.0%)

5 (31.3%)

20 (100.0%)

25 (36.2%)

 Positive

33 (100.0%)

11 (68.8%)

0 (0.0%)

44 (63.8%)

PR (n, %)

    

 Negative

12 (36.4%)

10 (62.5%)

20 (100.0%)

42 (60.9%)

 Positive

21 (63.6%)

6 (37.5%)

0 (0.0%)

27 (39.1%)

Tumor grade (n, %)

    

 Grade 1

4 (12.1%)

2 (12.5%)

0 (0.0%)

6 (8.7%)

 Grade 2

18 (54.5%)

5 (31.3%)

4 (20.0%)

27 (39.1%)

 Grade 3

11 (33.3%)

9 (56.3%)

16 (80.0%)

36 (52.2%)

Focality (n, %)

    

 Unifocal

22 (66.7%)

11 (68.8%)

11 (55.0%)

44 (63.8%)

 Multifocal

11 (33.3%)

5 (31.3%)

9 (45.0%)

25 (36.2%)

Breast surgery (n, %)

    

 Lumpectomy

10 (31.3%)

5 (31.3%)

6 (30.0%)

21 (30.9%)

 Mastectomy

22 (68.8%)

11 (68.8%)

14 (70.0%)

47 (69.1%)

Axillary surgery (n, %)

    

 SLNB

8 (24.2%)

4 (24.2%)

5 (25.0%)

17 (24.6%)

 ALND

24 (72.7%)

11 (68.8%)

12 (60.0%)

47 (68.1%)

 SLNB/MARI

1 (3.0%)

1 (6.3%)

3 (15.0%)

5 (7.2%)

  1. ALND, axillary lymph node dissection; BR, Bloom-Richardson; cN, clinical nodal; cT, clinical tumor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; ILC, invasive lobular carcinoma; MARI, marking the axilla with radioactive iodine seeds; NST, no specific type; PET, positron emission tomography; PR, progesterone receptor; SLNB, sentinel lymph node biopsy; TN, triple negative
Back to article page